Immunogenicity of Yellow Fever Vaccine Coadministered With MenAfriVac in Healthy Infants in Ghana and Mali

Panchali Roy Chowdhury,1 Christian Meier,1 Hewad Laraway,1 Yuxiao Tang,2 Abraham Hodgson,3 Samba O. Sow,4 Godwin C. Enwere,5 Brian D. Plikaytis,6,a Prasad S. Kulkarni,7 Marie-Pierre Preziosi,5,8 and Matthias Niedrig1

1Centre for Biological Threats and Special Pathogens, Robert Koch Institut, Berlin, Germany; 2Meningitis Vaccine Project, PATH, Seattle, Washington; 3Navrongo Health Research Centre, Ghana Health Service, Navrongo, Ghana; 4Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali; 5Meningitis Vaccine Project, PATH, Ferney-Voltaire, France; 6Centers for Disease Control and Prevention, Atlanta, Georgia; 7Serum Institute of India Limited, Pune; and 8Meningitis Vaccine Project, Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland

Background. Yellow fever (YF) is still a major public health problem in endemic regions of Africa and South America. In Africa, one of the main control strategies is routine vaccination within the Expanded Programme on Immunization (EPI). A new meningococcal A conjugate vaccine (PsA-TT) is about to be introduced in the EPI of countries in the African meningitis belt, and this study reports on the immunogenicity of the YF-17D vaccines in infants when administered concomitantly with measles vaccine and PsA-TT.

Methods. Two clinical studies were conducted in Ghana and in Mali among infants who received PsA-TT concomitantly with measles and YF vaccines at 9 months of age. YF neutralizing antibody titers were measured using a microneutralization assay.

Results. In both studies, the PsA-TT did not adversely affect the immune response to the concomitantly administered YF vaccine at the age of 9 months. The magnitude of the immune response was different between the 2 studies, with higher seroconversion and seroprotection rates found in Mali vs Ghana.

Conclusions. Immunogenicity to YF vaccine is unaffected when coadministered with PsA-TT at 9 months of age. Further studies are warranted to better understand the determinants of the immune response to YF vaccine in infancy.

Clinical Trials Registration. ISRCTN82484612 (PsA-TT-004); PACTR201110000328305 (PsA-TT-007).

Keywords. yellow fever vaccine; group A meningococcal conjugate vaccine; coadministration; microneutralization assay; Africa.

Yellow fever (YF), an acute viral hemorrhagic fever caused by yellow fever virus, remains among the most feared diseases. Primary endemic regions for YF are sub-Saharan Africa, Central America, and South America. At present, the disease still affects approximately 200,000 persons with 30,000 deaths annually, despite the availability of YF vaccines. YF vaccines are live attenuated vaccines based on the 17D attenuation variant and are considered among the most effective and safe vaccines in use today, with >400 million people vaccinated [1–6].

One of the main public health concerns is the maintenance of high levels of population immunity in endemic regions through routine childhood immunization. The YF-17D vaccine was added to the Expanded Programme on Immunization (EPI) in YF-endemic countries in Africa in 1991, in concomitant administration with measles vaccine in infants at 9 months of age [7]. However, there are still only limited data available on safety and immunogenicity when YF-17D vaccine is coadministered with other vaccines. The immune response is usually not affected when coadministered with other vaccines such as measles [8, 9]; however, some reports have described significantly lower immune
responses to YF, mumps, and rubella following coadministration of YF and measles, mumps, and rubella vaccine [10].

A monovalent group A meningococcal conjugate vaccine (PsA-TT, MenAfriVac), developed through the Meningitis Vaccine Project (MVP), is about to be introduced in routine EPI in countries of the African "meningitis belt," with a single dose at 9 months of age concomitantly administered with YF and measles vaccines [11]. We report here the immune response to YF vaccine following coadministration with PsA-TT in 2 infant clinical trials conducted in Ghana and in Mali.

METHODS

The studies were designed and conducted in accordance with the Good Clinical Practice guidelines established by the International Conference on Harmonisation, and with the Declaration of Helsinki, and approved by the competent ethics committees and regulatory authorities. Both studies were coordinated by MVP, a partnership between the World Health Organization (WHO) and PATH, aiming to develop an affordable, monovalent, group A meningococcal conjugate vaccine through a public–private partnership with the vaccine manufacturer Serum Institute of India, Ltd.

Study A

The first study (PsA-TT-004) was a phase 2, double-blind, randomized, controlled, dose-ranging study to evaluate the safety, immunogenicity, dose response, and schedule response of PsA-TT administered concomitantly with local EPI vaccines in healthy infants. The study was conducted in rural northern Ghana from November 2008 to May 2012 and the main study results are reported by Hodgson et al (unpublished data). A total of 1200 infants were randomized to receive primary vaccination into 6 study groups of 200 subjects each. Subjects’ group allocation during the study is presented in Table 1. Subjects in all groups received EPI vaccines (measles and YF) at 9 months of age. The EPI vaccines were administered alone in groups 3 and 4, and concomitantly with a second dose of PsA-TT with different dosages in groups 1A (10 µg), 1B (5 µg), and 1C (2.5 µg) and with a single dose of PsA-TT (10 µg) in group 2. Group 4 was the control group for this vaccine period (no blood draw was performed in group 3 at this time point).

Study B

The second study (PsA-TT-007) was a phase 3, double-blind, randomized controlled study to evaluate the immunogenicity and safety of different schedules and formulations of PsA-TT administered concomitantly with local EPI vaccines in healthy infants and toddlers. The study was conducted in urban Mali from March 2012 to September 2013, and the main study results are reported by Hodgson et al (unpublished data). A total of 1500 infants were randomized to receive primary vaccination into 5 study groups of 300 subjects each. Subjects’ group allocation during the study is presented in Table 1. Subjects in all groups received EPI vaccines (measles and YF) at 9 months of age. The EPI vaccines were administered alone in group 3,

Table 1. Summary Description of 2 Infant Studies and Demographics of Study Subjects at Yellow Fever Vaccination

| Study ID | Study Site  | No. of Subjects Enrolled | No. of Subjects by Study Arm | Vaccines Administered by Study Arm |
|----------|-------------|--------------------------|-------------------------------|------------------------------------|
|          |             | 1200/200 per group       |                               | At Age 14–18 wk: DTwPHBVHib – OPV in All Study Groups | At Age 9–12 mo: Measles – YF in All Study Groups | At Age 12–18 mo: DTwPHBVHib in All Study Groups | At Age 15–18 mo: Measles /Rubella in All Study Groups | No. of Subjects at YF Vaccination, Sex: F/M, Age, Median (Min-Max) |
| Study A: | Navrongo, Ghana | 1200/200 per group       | 1A PsA-TT 10 µg               | PsA-TT 10 µg                      | NA                                  | 1153                                        | 573/580                                        | 9 mo (8–13 mo) |
|          |             | 1B PsA-TT 5 µg           |                               |                                   |                                    |                                              |                                                |                                |
|          |             | 1C PsA-TT 2.5 µg         |                               |                                   |                                    |                                              |                                                |                                |
|          |             | 2                         | PsA-TT 10 µg                  | PsA-TT 10 µg                      | NA                                  | 1153                                        | 573/580                                        | 9 mo (8–13 mo) |
|          |             | 3                         |                                 |                                   |                                    |                                              |                                                |                                |
|          |             | 4                         |                                 |                                   |                                    |                                              |                                                |                                |
| Study B: | Bamako, Mali | 1500/300 per group       | 1A NA                         | PsA-TT 10 µg                      | NA                                  | 1500                                        |                                                |                                |
|          |             | 1B                         | PsA-TT 5 µg                  | PsA-TT 5 µg                       |                                    |                                              |                                                |                                |
|          |             | 2A                         | PsA-TT 10 µg                  | PsA-TT 10 µg                      |                                    |                                              |                                                |                                |
|          |             | 2B                         | PsA-TT 5 µg                  | PsA-TT 5 µg                       |                                    |                                              |                                                |                                |
|          |             | 3                         |                                 |                                   |                                    |                                              |                                                |                                |

Abbreviations: DTwPHBVHib, diphtheria, tetanus, whole-cell pertussis (DTwP), hepatitis B virus (HBV), Haemophilus influenzae type b (Hib) vaccines; NA, not applicable; OPV, oral polio vaccine; PsA-TT, group A meningococcal conjugate vaccine; YF, yellow fever.
and concomitantly with PsA-TT vaccine with different dosages in groups 1A (10 µg), 1B (5 µg), 2A (10 µg), and 2B (5 µg). Group 3 was the control group for this vaccine period.

**Yellow Fever Vaccines**

**Study A**
The live attenuated YF virus vaccine strain 17D, substrain 17DD (Fiocruz Yellow Fever Vaccine, manufactured by Bio-Manguinhos/Fiocruz) was used. The vaccine contained \( \geq 1000 \text{LD}_{50} \) (lethal dose, 50%) units per dose (0.5 mL); that is, the vaccine concentration per dose was between 4.34 \( \log_{10} \) plaque-forming units (PFU) and 4.56 \( \log_{10} \) PFU (2 batches, No. 085VFA051Z and No. 085UF011Z, were used). The presentation was in 10-dose vials of freeze-dried vaccine to be reconstituted with diluent.

**Study B**
The live attenuated YF virus vaccine strain 17D (manufactured by Federal State Unitary Enterprise of Chumakov Institute of Poliomyelitis and Viral Encephalitis, Russian Academy of Medical Sciences) was used. This vaccine contains \( \geq 1000 \text{LD}_{50} \) units per dose (0.5 mL); that is, the vaccine concentration per dose was between 4.5 \( \log_{10} \) PFU and 4.7 \( \log_{10} \) PFU (a single batch was used, No. 090). The presentation was in 5-dose vials of freeze-dried vaccine to be reconstituted with diluent.

**Immunogenicity**
Blood samples obtained before and 4 weeks after YF vaccination were tested for neutralizing antibodies against YF virus in the Robert Koch Institute (RKI) microneutralization assay using the YF-17D target virus strain produced at the RKI in a concentration of 100 TCID_{50} (tissue culture infectious dose, 50%)/well (ie, 100 µL) [12]. Neutralization titers (NTs) were expressed as the reciprocal serum dilutions yielding \( \geq 50\% \) neutralization after 5 days, that is, blocking at least 1 of 2 duplicate infections.

All serum samples were first heat-inactivated at 56°C for 30 minutes; then, 2-fold dilutions of each serum sample were prepared in 96-well plates to obtain dilutions of 1:4 to 1:256. To each serum dilution the same volume of YF-17D virus was added. The serum–virus mixture along with positive and negative control sera was incubated for 1 hour at 37°C in a 5% carbon dioxide, 90% humidity atmosphere. Meanwhile, porcine kidney epithelial (PS) cells (10 mL of 6 \( \times \) 10^5 cells/mL) were prepared. PS cells were washed with phosphate-buffered saline, detached by the addition of HyQTase (incubation for 10 minutes at 37°C), and then diluted in Dulbecco’s modified Eagle medium to the required concentration. A volume of 100 µL of the correctly adjusted cell concentration was then added to each well of a new 96-well plate. After 1 hour of incubation, 100 µL of each serum–virus solution was transferred in duplicates to the wells with the cells. For each serum sample, cytotoxicity (to exclude possible cytotoxic effects of the serum on the cells), cell, and virus controls were used. The plates were incubated for 5 days at 37°C in a 5% carbon dioxide, 90% humidity atmosphere, and then cells were fixed with 3.7% formaldehyde and stained with naphthalene black solution. Plates were evaluated and each well was observed under a microscope for signs of cytopathic effects in the infected cells. The serum dilution, which prevented 50% of replicate inoculation (ie, in which 1 of 2 duplicate infections was blocked), was determined as the NT. Whenever infection was prevented in both duplicate wells (100%) at a particular dilution and present in both duplicates (100%) at the next dilution, the NT was determined as the geometric mean of the 2 dilutions. If complete infection was observed at all serum dilutions, the NT was determined as \( <1:4 \) the starting serum dilution.

Seroconversion was defined as an NT at least twice as high as that at baseline (\( \geq 2\)-fold rise) 28 days after immunization. Sero-protection was defined as an NT \( \geq 1:8 \).

**Statistical Analysis**
The neutralizing geometric mean titers (GMTs) between the vaccine groups at baseline and 4 weeks after vaccination were compared using analysis of variance (ANOVA) adjusted for baseline titers, age, and sex. Percentages of subjects with NTs \( \geq 2\)-fold rise and with NTs \( \geq 1:8 \) were calculated. The 95% CI for the difference in the proportions of subjects with these responses between the control group and a particular study vaccine group were conducted in the intention-to-treat population. Missing values were treated as missing at random. All tests were 2-sided with a significance level of .05.

Data analysis was performed using SAS, version 9.1.3.

**RESULTS**

**Study A**

**Study Population**
A total of 1153 subjects (96% of the 1200 subjects enrolled at age 14 weeks) received YF vaccination at a median age of 9 months with a sex ratio (F/M) of 0.99. The immune response to YF vaccine was assessed in all study subjects with sufficient volumes of sera (Table 2).

**YF Serum Neutralizing Antibody Titers**
Reverse cumulative distribution curves for YF NTs at baseline prior to vaccination and 4 weeks after vaccination, according
For the comparison of NT geometric mean titers (GMTs) between groups, the 2-fold rise in YF titers ranged from 2.4 (95% CI, 2.2–2.6) to 3.0 (95% CI, 2.8–3.3).

| Age      | Study ID       | Vaccine Group | No. Tested/ Vaccinated With Yellow Fever Vaccine | Yellow Fever NT Titer ≥1:8, % (95% CI) | Yellow Fever NT ≥2-Fold Rise, % (95% CI) | Yellow Fever NT, Geometric Mean Titer (95% CI) |
|----------|----------------|---------------|-------------------------------------------------|----------------------------------------|------------------------------------------|-----------------------------------------------|
| 9 mo     | Study A: PsA-TT-004 | Group 1A PsA-TT 10 µg (dose 2) | 174/193 | 79.3 (72.5–85.1) | 68.4 (60.9–75.2) | 16.6 (13.9–19.9) |
|          |                | Group 1B PsA-TT 5 µg (dose 2) | 162/191 | 74.7 (67.3–81.2) | 71.0 (63.3–77.8) | 15.0 (12.4–18.2) |
|          |                | Group 1C PsA-TT 2.5 µg (dose 2) | 177/194 | 67.8 (60.4–74.6) | 64.8 (57.2–71.8) | 12.1 (10.1–14.5) |
|          |                | Group 2 PsA-TT 10 µg (dose 1) | 160/189 | 70.0 (62.3–77.0) | 67.1 (59.2–74.3) | 12.6 (10.5–15.1) |
|          |                | Group 3 Control | . . . | . . . | . . . | . . . |
|          |                | Group 4 Control | 168/190 | 71.4 (64.0–78.1) | 67.1 (59.4–74.1) | 15.2 (12.5–18.6) |

| Study B: PsA-TT-007 | Group 1A PsA-TT 10 µg (dose 1) | 60/300 | 98.3 (91.1–100) | 98.3 (91.1–100) | 33.9 (28.9–39.7) |
|                    | Group 1B PsA-TT 5 µg (dose 1) | 60/300 | 96.7 (88.5–99.6) | 91.7 (81.6–97.2) | 33.3 (27.5–40.3) |
|                    | Group 2A PsA-TT 10 µg (dose 1) | 61/300 | 95.1 (86.3–99.0) | 93.4 (84.1–98.2) | 32.5 (26.8–39.4) |
|                    | Group 2B PsA-TT 5 µg (dose 1) | 59/300 | 96.6 (88.3–99.6) | 89.8 (79.2–96.2) | 31.6 (25.8–38.7) |
|                    | Group 3 Control | 60/300 | 96.7 (88.5–99.6) | 90.0 (79.5–96.2) | 29.1 (24.6–34.6) |

Abbreviations: CI, confidence interval; NT, neutralization titers; PsA-TT, group A meningococcal conjugate vaccine.

* No. of subjects tested at 28 days after vaccination.

Study A: The difference in ≥1:8 percentage was −7.9% (95% CI, −17.0 to 1.3) between group 4 and group 1A, −3.3% (95% CI, −12.8 to 6.4) between group 4 and group 1B, 3.6% (95% CI, −6.1 to 13.3) between group 4 and group 1C, and 1.4% (95% CI, −8.4 to 11.3) between group 4 and group 2; the difference in ≥2-fold rise percentage was −1.3% (95% CI, −11.2 to 8.6) between group 4 and group 1A, −3.9% (95% CI, −13.9 to 6.1) between group 4 and group 1B, 2.3% (95% CI, −7.8 to 12.3) between group 4 and group 1C, and −0.0% (95% CI, −10.2 to 10.2) between group 4 and group 2, 4 weeks after vaccination by Miettinen–Nurminen method. For the comparison of NT geometric mean titers (GMTs) between groups, the P value was >.05 (all groups) by analysis of variance (ANOVA) after adjusting for age, sex, and baseline titer.

Study B: The difference in ≥1:8 percentage was −1.7% (95% CI, −10.0 to 5.9) between group 3 and group 1A, 0.0% (95% CI, −8.5 to 8.5) between group 3 and group 1B, 1.6% (95% CI, −7.1 to 10.7) between group 3 and group 2A, and 0.1% (95% CI, −8.5 to 8.7) between group 3 and group 2B; the difference in ≥2-fold rise percentage was −8.3% (95% CI, −18.8 to 1.7) between group 3 and group 1A, −1.7% (95% CI, −13.1 to 9.6) between group 3 and group 1B, −3.4% (95% CI, −14.6 to 7.2) between group 3 and group 2A, and 0.2% (95% CI, −11.5 to 12.0) between group 3 and group 2B, 4 weeks after vaccination by Miettinen–Nurminen method. For the comparison of NT GMTs between groups, the P value was >.05 (all groups) by ANOVA after adjusting for age, sex, and baseline titer.

to study groups, are shown in Figures 1A and 2A. The proportion of subjects with YF NTs ≥1:8, with ≥2-fold YF NT rises as compared to baseline and the GMTs of YF fever NTs, at 28 days after vaccination and for each study group, is presented in Table 2.

At Baseline. As shown in Figure 1A, a handful of subjects had YF titers ≥1:8. Overall, the percentage of subjects with YF titers ≥1:8 was 4.5% (38/851), ranging from 0.6% (95% CI, .07%–3.4%) to 10.0% (95% CI, 5.9%–15.5%), in the vaccine groups. The GMTs of YF titers ranged from 2.4 (95% CI, 2.2–2.6) to 3.0 (95% CI, 2.8–3.3).

At 28 Days After Vaccination. The percentages of subjects with YF titers ≥1:8 ranged from 67.8% to 79.3% and were lower than the anticipated response rate (95%) in all groups. The noninferiority of the immune response elicited by YF vaccine administered concomitantly with the second dose of PsA-TT vaccine at different dosages (10 µg and 5 µg) to that elicited by YF vaccine alone was demonstrated—that is, the upper limits of the 95% CI for the differences were <10% between group 4 and each of groups 1A and 1B. In contrast, the same noninferiority was not confirmed when YF vaccine was administered concomitantly with the second dose of PsA-TT 2.5 µg vaccine or with the 1-dose 10 µg PsA-TT vaccine, with an upper limit of the CI of the difference of 13.3% between group 4 and group 1C and of 11.3% between group 4 and group 2, respectively (Table 2).

The percentages of subjects with a ≥2-fold response in YF titers with respect to baseline ranged from 64.8% to 71.0%. The noninferiority of the immune response elicited by YF vaccine administered concomitantly with the second dose of PsA-TT
vaccine at different dosages (10 µg and 5 µg) to that elicited by EPI vaccines alone at 28 days after vaccine administration was demonstrated for this endpoint as well; the upper limit of the 95% CI for the differences was <10% between group 4 and each of groups 1A and 1B. In contrast, the same noninferiority was not confirmed when YF vaccine was administered concomitantly with the second dose of PsA-TT 2.5 µg vaccine or with the 1-dose 10 µg PsA-TT vaccine; that is, the upper limit of the 95% CI for the differences was 12.3% between group 4 and group 1C and 10.2% between group 4 and group 2, respectively (Table 2).

YF neutralizing GMTs were similar in all groups, ranging from 12.1 to 16.6, with no statistically significant difference when groups were compared using ANOVA after adjusting for age, sex, and baseline titer (Table 2), and the distribution of YF NTs was consistently similar in all study groups (Figure 2A).

Four weeks postvaccination, analysis stratified by sex did not show any difference in the overall proportion of subjects with YF NTs ≥1:8 (72.6% [95% CI, 68.0%–76.9%] among girls and 72.7% [95% CI, 68.2%–76.8%] among boys) or with ≥2-fold YF neutralizing titer rises (68.8% [95% CI, 64.1%–73.3%] among girls and 66.5% [95% CI, 61.8%–71.0%] among boys), or in the overall GMTs of YF fever neutralizing titers (14.0 [95% CI, 12.4–15.7] among girls and 14.4 [95% CI, 12.8–16.2] among boys).
Study B
Study Population
All 1500 subjects enrolled received YF vaccination at a median age of 9 months, with a sex ratio (F/M) of 0.94. The immune response to YF vaccine was assessed in a random subsample of 300 subjects with equal distribution in all study groups (60 subjects per group).

YF Serum Neutralizing Antibody Titers
Reverse cumulative distribution curves for YF NTs at baseline prior to vaccination and 4 weeks after vaccination, according to study groups, are shown in Figures 1B and 2B. The proportion of subjects with YF NTs ≥1:8, with ≥2-fold YF NT rises as compared to baseline and the GMTs of YF fever NTs, at 28 days after vaccination and for each study group, is presented in Table 2.

At Baseline. The YF NT at baseline prior to vaccination at 9 months of age was consistently low in all study groups (Figure 1B). The percentages of subjects with YF titers ≥1:8 was 4.0% overall (12/300), ranging from 0.0% (95% CI, 0.0%–4.9%) to 6.7% (95% CI, 1.8%–16.2%) in the different study groups. The GMTs of YF titers ranged from 3.0 (95% CI, 2.7–3.3) in group 1B to 3.3 (95% CI, 2.9–3.7) in group 3.

At 28 Days After Vaccination. The percentages of subjects with YF titers ≥1:8 were similar in all groups, ranging from 95.1% to 98.3%, and above the anticipated response rate (95%). The noninferiority of the immune response elicited by YF vaccine administered concomitantly with PsA-TT at different dosages (10 µg and 5 µg) to that elicited by YF vaccine alone was demonstrated; that is, the upper limits of the 95% CI for the differences were <10% between group 3 and each of groups 1A, 1B, and 2B. However, the same noninferiority of group 2A (YF and PsA-TT 10 µg vaccines) to group 3 (YF vaccine alone) was not confirmed with respect to the same endpoint; that is, the upper limit of the 95% CI for the difference was ≥10% (10.7% between group 3 and group 2A) (Table 2).

The percentages of subjects with a ≥2-fold response in YF titer with respect to baseline ranged from 89.8% to 98.3%. The noninferiority of the immune response elicited by YF vaccine administered concomitantly with the first dose of PsA-TT at different dosages (10 µg and 5 µg) to that elicited by YF vaccine alone was demonstrated for this endpoint as well; that is, the upper limit of the 95% CI for the differences was <10% for each comparison of group 3 with groups 1A, 1B, and 2A. However, the same noninferiority of group 2B (YF and PsA-TT 5-µg vaccines) to group 3 (YF vaccine alone) was not confirmed with respect to the same endpoint; that is, the upper limit of the 95% CI for the difference was ≥10% (12.0% between group 3 and group 2B; Table 2).

YF neutralizing GMTs were similar in all groups, ranging from 29.1 to 33.9, with no statistically significant difference when groups were compared using ANOVA after adjusting for age, sex, and baseline titer (Table 2); in addition, the distribution of YF NTs was consistently similar in all study groups (Figure 2B).

Four weeks postvaccination, analysis stratified by sex did not show any difference in the overall proportion of subjects with YF titers ≥1:8 (94.9% [95% CI, 89.7%–97.9%] and 98.2% [95% CI, 94.8%–99.6%] among girls and boys, respectively) or with ≥2-fold YF NT rises (91.2% [95% CI, 85.1%–95.4%] and 93.9% [95% CI, 89.1%–97.0%] among girls and boys, respectively), or in the overall GMTs of YF fever NTs (29.4 [95% CI, 26.1–33.1] and 34.4 [95% CI, 30.8–38.3] among girls and boys, respectively).

DISCUSSION

In both studies, PsA-TT (at 10-µg, 5-µg, and 2.5-µg dosages) did not adversely affect the immune response to the concomitantly administered YF vaccine at the age of 9 months.

In both studies, the noninferiority of each PsA-TT vaccine group to the control group (YF/measles vaccines alone) was demonstrated for the majority of pairwise comparisons of percentages of subjects achieving seroconversion and seroprotection 4 weeks after immunization. In a few instances, such noninferiority was not confirmed, likely due to low statistical power, resulting from low seroconversion rates in study A or from small sample size in study B. In study A, 68%–79% of subjects reached YF seroprotection (NT ≥1:8) at 4 weeks after immunization (ie, significantly less than the expected 95%), resulting in a low power in testing noninferiority. In study B, YF endpoints were measured only in a random subsample of subjects (300/1500, 60 subjects per study group), also resulting in limited power. However, there was no statistically significant difference among all study groups in each study in YF virus neutralizing antibody GMTs 4 weeks after immunization after adjusting for age, sex, and prevaccination titer.

The immune response to YF, as measured by NTs 4 weeks after immunization, was different between the 2 studies, with a higher seroconversion rate, seroprotection rate, and GMTs (93%, 97% and 32, respectively, in study B conducted in Mali, vs 68%, 73%, and 14, respectively, in study A conducted in Ghana). Several determinants could explain this difference, such as vaccine strain, vaccine concentration, presence of maternal antibodies, and interference of other vaccines [14].

Two different vaccine substrains of YF-17D were used in the 2 studies: the 17DD strain in study A (Ghana) and the 17D-213/77 strain (a derivative of the 17D-204 substrain) in study B (Mali). The difference between these 2 vaccine substrains is the passage level (17D-204; 235–240; 17DD: 286–287) [15], but there are only minor differences when comparing nucleotide sequences of both the substrains [16]. Camacho et al and

Yellow Fever Vaccine With MenAfriVac in African Infants • CID 2015:61 (Suppl 5) • S591
Nascimento Silva et al performed studies in which both vaccine substrains, 17DD and 17D-213, were tested for immunogenicity in adults and infants [10, 17], with no significant difference in immune response. Seroconversion rates were 98% in one study and 70%–88% in the other study. Immunogenicity studies of YF-17D vaccines in infants show that immune responses tend to be lower in infants than in adults, with seroconversion rates ranging from 70% to 88.8% [8, 10, 17], consistent with our findings in study A. Interestingly, Nascimento Silva et al have also reported a significant difference in seroconversion rates when administering YF-17D alone or simultaneously with measles, mumps, and rubella vaccine (86.5% vs 69.5%) [10]. Similar rates were reported in another study, where 9- to 11-month-old infants received the YF-17D vaccine concomitantly with measles vaccine [14] with a seroconversion rate of 72%, consistent with that found in study A.

The difference in immune response between the 2 studies could also be related to a differential amount of viral particles in the vaccines. In 2009, a WHO expert committee defined a minimum amount of viral particles per dose as 3.0 log10 international units, that is, approximately equivalent to 3.73 log10 PFU. In 2013, the latter concentration was supported by a dose-response study of the YF-17DD vaccine conducted by Martins et al, who demonstrated that this minimal dose was as immunogenic as higher doses, with little differences in response rates [15]. The concentrations of the vaccines, which were used for both our studies, were above this concentration (study A: 4.34–4.56 log10 PFU; study B: 4.5–4.7 log10 PFU). However, viral concentrations are determined by titrating the virus on susceptible cells. Most commonly, Vero or P5 cells are used for this purpose, with titers being higher when performing the titration on Vero cells vs P5 cells (a difference ranging from 0.5 to 1 log10). The method for the determination of concentrations is not published and it would be valuable to test both vaccines together on the same cell system.

WHO indicated in 2013 that a single dose of the YF-17D vaccine provides lifelong protective immunity against YF disease and that a booster dose is no longer necessary [18]. This is consistent with the systematic review of the efficacy and duration of immunity after YF vaccination conducted by Gotuzzo et al to assess the need for a booster dose every 10 years [19]. Their findings indicate that, in most studies, seroconversion rates following YF vaccination were >90% and remained >75% several years after immunization. Furthermore, they found some indications that a YF booster dose would only lead to a minor or short-lived increase in neutralizing antibodies due to preexisting antibodies from primary vaccination [19], and they concluded that a YF booster dose would not be needed. Given the rather low neutralizing GMTs found after vaccination in study A, the question may arise whether these titer values are maintained throughout life. Conducting a serosurvey in these infants in 3–5 years would be warranted to evaluate whether titers are maintained or decline with time [18, 19].

The presence of maternal antibodies also plays a role in the immunologic response in infants [20, 21]. The median age at vaccination (9 months) and the prevaccination titers were similar and consistently low in both studies, with 4.5% and 4.0% of the infants with titers ≥1.8 prior to vaccination. Therefore, presence of maternal antibodies cannot explain the different levels of response observed in our 2 studies.

Sex differences in response to YF vaccine have been reported, with contradictory reports of higher responses either among adult males or among adult females [22, 23]. No difference in the immune response to YF vaccine according to sex was found in our studies, so more studies are required to analyze sex differences in immune responses to the YF-17D vaccine in infants.

In conclusion, concomitant administration of the PsA-TT does not affect the response to YF vaccine in African infants. Differences in the postvaccination seroconversion and seroprotection rates in the 2 studies were observed, confirming the need to further document the immune response to YF-17D vaccine in infants.

Notes

Acknowledgments. The authors thank Manisha Ginde, Arati Borkar, and Nija Sasidharan from Diagno Search Life Sciences Pvt, Ltd, for their ambitious engagement in the continuous evaluation of the quality of the YF NT assay according to international standards and supervision of the accreditation process, and the Meningitis Vaccine Project team, in particular, Julie Chaumont, Kajsa Hultgren, and Lionel Martellet for their support. Our gratitude also goes to Anette Teichmann and Katharina Holschbach-Bussian for facilitating the accreditation of the YF NT according to national regulations. For providing further details on the YF vaccines, we also thank Alexander Lukashev from the Russian Academy of Medical Sciences and Maria Fernandes from Bio-Manguinhos/Fiocruz.

Disclaimers. 1) The authors and editors alone are responsible for the views expressed in this publication and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated; 2) The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of PATH or the World Health Organization (WHO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement; 3) The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by PATH or WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

Supplement sponsorship. This article appears as part of the supplement “The Meningitis Vaccine Project: The Development, Licensure, Introduction, and Impact of a New Group A Meningococcal Conjugate Vaccine for Africa,” sponsored by the Meningitis Vaccine Project through a grant from the Bill & Melinda Gates Foundation.

Potential conflicts of interest. M.-P. P. has received institutional grant support from PATH, Gavi the Vaccine Alliance, the Shefa Fund hosted by the Swiss Philanthropy Foundation, the National Philanthropic Trust, the Research Council of Norway, and the US Agency for International Development, and has received travel support from PATH and the Research Council of Norway. All other authors report no potential conflicts.
All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Tomori O. Yellow fever: the recurring plague. Crit Rev Clin Lab Sci 2004; 41:391–427.
2. Monath TP. Yellow fever: an update. Lancet Infect Dis 2001; 1:11–20.
3. Staples JE, Monath TP. Yellow fever: 100 years of discovery. JAMA 2008; 300:960–2.
4. Barrett AD, Monath TP, Barban V, Niedrig M, Teuwen DE. 17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005. Vaccine 2007; 25:2758–65.
5. Stock NK, Boschetti N, Herzog C, Appelhans MS, Niedrig M. The phylogeny of yellow fever virus 17D vaccines. Vaccine 2012; 30:989–94.
6. Roukens AH, Visser LG. Yellow fever vaccine: past, present and future. Expert Opin Biol Ther 2008; 8:1787–95.
7. World Health Organization. Yellow fever—Technical Consensus Meeting in Emerging and Other Communicable Diseases, Surveillance and Control. 2–3 March 1998. Geneva, Switzerland: WHO.
8. Stefano I, Sato HK, Pannuti CS, et al. Recent immunization against yellow fever vaccines? Vaccine 1999; 17:1042–6.
9. Michel R, Berger F, Ravelonarivo J, et al. Observational study on immune response to yellow fever vaccine. Vaccine 1999; 17:1042–6.
10. Nascimento Silva JR, Camacho LA, Siqueira MM, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine 2011; 29:6327–34.
11. World Health Organization. Meningococcal A conjugate vaccine: updated guidance, February 2015. Wkly Epidemiol Rec 2015; 90: 57–68.
12. Assay Accreditation. Registration number of the certificate of accreditation. D-ML-13113-01-13. Frankfurt: DAkkS (national accreditation body for the Federal Republic of Germany. 2013.
13. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213–26.
14. Collaborative Group for Studies With Yellow Fever Vaccine. Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program. Vaccine 2007; 25:3118–23.
15. Martins RM, Maia Mde L, Farias RH, et al. 17DD yellow fever vaccine: a double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccin Immunother 2013; 9:879–88.
16. World Health Organization. Recommendations to assure the quality, safety and efficacy of live attenuated yellow fever vaccines. Geneva, Switzerland: WHO, 2010.
17. Camacho LA, Freire Mda S, Leal Mda L, et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 2004; 38:671–8.
18. Vaccines and vaccination against yellow fever. WHO position paper—June 2013. Wkly Epidemiol Rec 2013; 88:269–83.
19. Gotuzzo E, Yactayo S, Córdova E. Review article: efficacy and duration of immunity after yellow fever vaccination: systematic review on the need of a booster every 10 years. Am J Trop Med Hyg 2013; 89:434–44.
20. Kim D, Huey D, Oglesbee M, Niewiesk S. Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies. Blood 2011; 117:6143–51.
21. Gagneur A, Pinquier D, Aubert M, et al. Kinetics of decline of maternal measles virus-neutralizing antibodies in sera of infants in France in 2006. Clin Vaccine Immunol 2008; 15:1845–50.
22. Monath TP, Nichols R, Archambault WT, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002; 66:533–41.
23. Pfister M, Kürsteiner O, Hülfter H, et al. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg 2005; 72:339–46.